Transcatheter valve‐in‐ring implantation of a repositionable valve system for treatment of severe mitral regurgitation

Lauterbach, Michael; Sontag, Bruno; Paraforos, Alexandros; Friedrich, Ivar; Hauptmann, Karl-Eugen

doi:10.1002/ccd.26376

Cited by 4 publications

(3 citation statements)

References 14 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 2009 to March 31, 2018, 66 published reports describing 172 patients undergoing TMVIV implantation for degenerated mitral bioprostheses and 35 articles describing 73 patients undergoing TMVIR implantation for failed annuloplasty rings were identified (Figure ). The patients were diagnosed with MR, MS, or mixed lesions according to the articles but the failure modes of 34 patients were unknown.…”

Section: Resultsmentioning

confidence: 99%

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Chen

Cheng

et al. 2018

J Card Surg

View full text Add to dashboard Cite

BackgroundTranscatheter mitral valve‐in‐valve (TMVIV) and valve‐in‐ring (TMVIR) implantation for degenerated mitral bioprostheses and failed annuloplasty rings have recently emerged as treatment options for patients deemed unsuitable for repeat surgery.MethodsA systematic literature review was conducted to summarize the data regarding the baseline characteristics and clinical outcomes of patients undergoing TMVIV and TMVIR procedures.ResultsA total of 245 patients (172 patients who underwent TMVIV surgery and 73 patients who underwent TMVIR surgery) were included in the study; 93.5% of patients experienced successful TMVIV or TMVIR implantation. The mortality rates at discharge, 30 days, and 6 months were 5.7%, 8.1%, and 23.4%, respectively. The transapical (TA) access route was used in most procedures (55.2%). The TA and transseptal (TS) access routes resulted in similar outcomes. No significant differences were observed in the short‐term outcomes between the patients who developed mitral stenosis versus mitral regurgitation as the mode of failure.ConclusionsTMVIV and TMVIR implantation for degenerated mitral bioprostheses and failed annuloplasty rings are safe and effective. Both procedures, via TA or TS access, can result in excellent short‐term clinical outcomes in patients with mitral stenosis or regurgitation, but long‐term follow‐up data are currently lacking to determine the durability of these procedures.

show abstract

Section: Resultsmentioning

confidence: 99%

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Chen

Cheng

et al. 2018

J Card Surg

View full text Add to dashboard Cite

show abstract

“…Five papers described reported transcatheter mitral valvein-ring procedures encompassing 20 patients (22,(27)(28)(29)(30). The mean patient age was 63.6±10.3 years with a mean follow-up duration of 126.4±158.0 days.…”

Section: Valve-in-ring Proceduresmentioning

confidence: 99%

Novel mitral valve technologies—transcatheter mitral valve implantation: a systematic review

Flynn¹,

Wilson-Smith²,

Yan³

2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

Background: Valvular heart disease is an important cause of morbidity and mortality throughout the world; in industrialized nations, mitral regurgitation (MR) is the most common valvular lesion. Untreated, severe MR has a poor prognosis, with a 5-year mortality rate of up to 50%. Surgical repair of symptomatic, severe primary MR has been demonstrated to improve survival. The aim of this review is to assess the early outcomes of newly developed transcatheter mitral valve implantation technologies for the treatment of secondary native valve disease. Furthermore, the outcomes of patients receiving transcatheter treatment of regurgitant failure of surgically repaired or replaced mitral valve has also been addressed. Methods: A systematic review of twenty-five studies assessing the outcomes of patients undergoing transcatheter mitral valve implantation for native mitral regurgitation or failed prior surgical repair or bioprosthetic replacement was carried out. Results: The outcomes of 112 patients undergoing transcatheter mitral valve replacement for secondary mitral regurgitation using six different valve systems were assessed. There were 15 early deaths and 24 deaths over the follow-up period. The outcomes of 44 patients undergoing transcatheter valve-in-valve replacement were assessed with an overall mortality of ten patients. There were 20 patients included who had valve-in-ring transcatheter mitral replacement for previous failed repair. The total mortality was five patients during the follow-up period. Conclusions: Transcatheter mitral valve implantation represents a new evolution in management of valvular disease and affords management options to patients who historically may not have been offered treatment. Early results have demonstrated some promise and improvements in technology, imaging modalities and patient selection will surely result in a reliable and durable valve.

show abstract

“…11 Evolving transcatheter heart technology has expanded the options of treating degenerated post-surgical valves to using transcatheter heart valve (THV) implantation for the mitral position. [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] State-of-the-art transcatheter therapy in failed mitral valve surgeries use balloon-expandable THVs, mostly from the Edwards Lifesciences' family of valves (SAPIEN, SAPIEN XT, SAPIEN 3). In general, the first step in the implantation process is identifying the correct prosthesis size for the intended location of implantation.…”

mentioning

confidence: 99%

Transseptal Transcatheter Mitral Valve Replacement for Post-Surgical Mitral Failures

Eng

Wang

2018

Interventional Cardiology Review

View full text Add to dashboard Cite

Post-surgical deterioration of mitral valve repairs or replacements may present a clinical dilemma due to the high-risk nature of repeat surgery. Recent advances in transcatheter techniques and surgery have enabled the implantation of balloon-expandable valves in the mitral position when surgical rings and valves are present. Valves may be implanted either via transseptal or transapical access, with a reported success rate between 88-100 %.

show abstract

Transcatheter valve‐in‐ring implantation of a repositionable valve system for treatment of severe mitral regurgitation

Abstract: Transapical valve-in-ring implantation of the repositionable Lotus valve system in the mitral position is a feasible and promising option that merits further evaluation. © 2015 Wiley Periodicals, Inc.

Cited by 4 publications

References 14 publications

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Novel mitral valve technologies—transcatheter mitral valve implantation: a systematic review

Transseptal Transcatheter Mitral Valve Replacement for Post-Surgical Mitral Failures

Contact Info

Product

Resources

About